Cholecystokinin/opioid interactions

Brain Research

Volumn 848, Issue 1-2, 1999, Pages 78-89

  Wiesenfeld Hallin, Zsuzsanna ^a   De Araúja Lucas, Guilherme ^a   Alster, Pawel ^a   Xu, Xiao Jun ^a   Hökfelt, Tomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cholecystokinin; Immunohistochemistry; Inflammation; Microdialysis; Morphine; Neuropathy; Neuropeptide; Opioid; Spinal cord

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DELTAKEPHALIN; ENDORPHIN; ENKEPHALIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MORPHINE; NALOXONE; NEUROPEPTIDE; OPIATE; OPIATE PEPTIDE; OPIATE RECEPTOR; POTASSIUM; PROGLUMIDE; TACHYKININ;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; CONTROLLED STUDY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NERVE INJURY; NEUROPATHY; NONHUMAN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; RAT; REVIEW; SPINAL CORD; SPINAL CORD DORSAL HORN;

EID: 0342680060     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01978-2     Document Type: Article

References (165)

1. Abelson J.L. Cholecystokinin in psychiatric research: a time for cautious excitement. J. Psychiatric Res. 29:1995;389-396.
2. Afifiy E.A., Law P.Y., Riedl M., Elde R., Loh H.H. Role of carboxyl terminus of mu- and delta-opioid receptor in agonist-induced down-regulation. Mol. Brain Res. 54:1998;24-34.
3. S.P.H. Alexander, J.A. Peters, Receptor and ion channel nomenclature supplement, Trends Pharmacol. Sci., (1998) 26-27.
4. Allard B., Beinfeld M.C. Vasoactive intestinal polypeptide (VIP) inhibits potassium-induced release of cholecystokinin (CCK) from rat caudato-putamen but not from cerebral cortex. Neuropeptides. 8:1986;287-293.
5. Arden J.R., Segredo V., Waing Z., Lameh J., Sadée W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tragged mu-opioid receptor expressed in HEK 293 cells. J. Neurochem. 65:1995;1636-1645.
6. Arnér S., Meyerson B.A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 33:1988;11-23.
7. Arvidsson U., Riedl M., Chakrabarti S., Lee J.H., Nakano A.H., Dado R.J., Loh H.H., Law P.Y., Wessendorf M.W., Elde R. Distribution and targeting of a mu-opioid receptor 1 in brain and spinal cord. J. Neurosci. 15:1995;3328-3341.
8. Baber N.S., Dourish C.T., Hill D.R. The role of CCK, caerulein, and CCK antagonists in nociception. Pain. 39:1989;307-328.
9. Barbaz W.L., Autry F.G., Ambrose N.R., Hall, Liebman J.M. Antinociceptive profile of sulfated CCK-8. Comparison with CCK-4, unsulfated CCK-8 and other neuropeptides. Neuropharmacol. 25:1986;823-829.
10. Bayliss W.M., Starling E.H. On the causation of the so-called peripheral reflex secretion of the pancreas. Proc. Roy. Soc. 69:1902;352-353.
11. Beinfeld M.C., Meyer D.K., Eskay R.L., Jensen R.T., Brownstein M.J. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rats as determined by radioimmunoassay. Brain Res. 212:1981;51-57.
12. 2+ and the regulation of neurotransmitter secretion. Curr. Op. Neurobiol. 7:1997;316-322.
13. Benoliel J.J., Bourgoin S., Mauborgne A., Legrand J.C., Hamon M., Cesselin F. Differential inhibitory/stimulatory modulation of spinal CCK release by mu and delta opioid agonists and selective blockade of mu-dependent inhibition by kappa receptor stimulation. Neurosci. Lett. 124:1991;204-207.
14. Benoliel J.J., Bourgoin S., Mauborgne A., Pohl M., Legrand J.C., Hamon M., Cesselin F. GABA, acting at both GABAA and GABAB receptors, inhibits the release of cholecystokinin-like material from the rat spinal cord in vitro. Brain Res. 590:1992;255-262.
15. Berridge M.J. Inositol triphosphate and calcium signalling. Nature. 361:1993;315-325.
16. Besse D., Lombard M.C., Zajac J.M., Roques B.P., Besson J.M. Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res. 521:1990;15-22.
17. Besse D., Weil-Fugazza J., Lombard M.C., Butler S.H., Besson J.M. Monoarthritis induces complex changes in mu-, delta-, and kappa-opioid binding sites in the superficial dorsal horn of the rat spinal cord. Eur. J. Pharmacol. 223:1992;123-131.
18. Bhargava H.N., Yousif D.J., Matwyshyn G.A. Interactions of thyrotropin releasing hormone, its metabolites and analogues with endogenous and exogenous opiates. Gen. Pharmacol. 14:1983;565-570.
19. Bourgoin S., Benoliel J.J., Collin E., Mauborgne A., Pohl M., Hamon M., Cesselin F. Opioidergic control of the spinal release of neuropeptides. Possible significance for the analgesic effects of opioids. Fund. Clin. Pharmacol. 8:1994;307-321.
20. Brás J.M.A., Laporte A.-M., Benoliel J.J., Bourgoin S., Mauborgne A., Hamon M., Cesselin F., Pohl M. Effect of peripheral axotomy on cholecystokinin neurotransmission in the rat spinal cord. J. Neurochem. 72:1999;858-867.
21. Brog M.C., Beinfeld M.C. Cholecystokinin release from the rat caudate-putamen, cortex and hippocampus is increased by activation of the D1 dopamine receptor. J. Pharm. Exp. Therap. 260:1992;343-348.
22. Burford N.T., Tolbert L.M., Sadee W. Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I. Eur. J. Pharmacol. 342:1998;123-126.
23. Cesselin F. Opioid and anti-opioid peptides. Fundam. Clin. Pharmacol. 9:1995;409-433.
24. Chapman V., Honoré P., Buritova J., Besson J.M. Cholecystokinin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-fos expression in the spinal cord of the rat. Neuroscience. 67:1995;731-739.
25. Chen L., Huang L.M. Sustained potentiation of NMDA receptor mediated glutamate responses through activation of protein kinase C by a mu opioid. Neuron. 7:1991;319-326.
26. Childers S.R. Opioid receptor coupled second messenger systems. Life Sci. 48:1991;1991-2003.
27. Coderre T.J., Katz J., Vaccarino A.L., Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 52:1993;259-285.
28. Conrath-Verrier M., Dietl G., Tramu C. Cholecystokinin-like immunoreactivity in the dorsal horn of the spinal cord of the rat: a light and electron microscopic study. Neuroscience. 13:1984;871-885.
29. Contreras P.C., Takemori A.E. Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence. Life Sci. 34:1984;2559-2566.
30. Contreras P.C., Takemori A.E. Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte-stimulating hormone. J. Pharmacol. Exp. Therap. 299:1984;21-26.
31. Corbett A.D., Gillan M.G., Kosterlitz H.W., McKnight A.T., Peterson S.J., Robson L.E. Selectivities of opioid peptide analogues as agonists and antagonists at the delta-receptor. Br. J. Pharmacol. 83:1984;271-279.
32. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
33. Davies S.N., Lodge D. Evidence for involvement of N-methylaspartate receptors in 'wind-up' of class 2 neurons in the dorsal horn of the rat. Brain Res. 424:1987;402-406.
34. De Mesquita M.C., Beinfeld M.C., Crawley J.N. Microdialysis as an approach to quantitate the release of neuropeptides. Prog. Neuropsychopharmacol. Biol. Psychiatry. 14:1991;S5-S15.
35. Dickenson A.H. Neurophysiology of poorly responsive pain. Cancer Surveys. 21:1994;5-16.
36. A.H. Dickenson, Where and how do opioids act?, in: G.F. Gebhart, D.L. Hammond, T.S. Jensen (Eds.), Proceedings of the 7th World Congress on Pain, Progress in Pain Research and Management, Vol. 2, IASP Press, Seattle, 1994, pp. 525-551.
37. Dockray G.J. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature. 264:1976;568-570.
38. Dockray G.J. Cholecystokinin in rat cerebral cortex: identification, purification and characterization by immunochemical methods. Brain Res. 188:1980;155-165.
39. Dodd P.R., Edwardson J.A., Dockray G.J. The depolarization-induced release of cholecystokinin C-terminal octapeptide (CCK-8) from rat synaptosomes and brain slices. Reg. Peptides. 1:1980;17-29.
40. Dourish C.T., Hawley D., Iversen S.D. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by cholecystokinin antagonist L-364.718. Eur. J. Pharmacol. 147:1988;469-472.
41. Draisci G., Iadarola M.J. Temporal analysis of increases in c-fos, preprodynorphin and preproenkephalin mRNAs in rat spinal cord. Mol. Brain Res. 6:1989;31-37.
42. Dubner R., Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammaton. Trends Neurosci. 15:1992;96-103.
43. Dunlop J. CCK receptor antagonists. Gen. Pharmacol. 31:1998;519-524.
44. Emson P.C., Lee C.M., Rehfeld J.F. Cholecystokinin octapeptide: vesicular localization and calcium dependent release from rat brain in vitro. Life Sci. 26:1980;2157-2163.
45. P.C. Emson, P.D. Marley, Cholecystokinin and vasoactive intestinal polypeptide, in: L. Iversen, S.D. Iversen, S.H. Snyder (Eds.), Handbook of Psychopharmacology, Vol. 16, Plenum, New York, 1983, pp. 255-306.
46. Faris P.L. Opiate antagonistic function of cholecystokinin in analgesia and energy balance systems. Ann. N.Y. Acad. Sci. 448:1985;437-447.
47. Faris P.L., Komisaruk B., Watkins L.R., Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 219:1983;310-312.
48. Faris P.L., MacLaughlin C.L., Baile C.A., Loney J.W., Komisaruk B.R. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science. 226:1984;1215-1217.
49. Fields H.L., Emson P.C., Leigh B.K., Gilbert R.F., Iversen L.L. Multiple opiate receptors on primary afferent fibers. Nature. 284:1980;351-353.
50. Fleetwood-Walker S.M., Mitchell R., Hope P.J., Molony V., Iggo A. An alpha 2 receptor mediates the selective inhibition by noradrenaline of nociceptive responses of identified dorsal horn neurons. Brain Res. 334:1985;243-254.
51. Friedman H.J., Jen M.F., Chang J.K., Lee N.M., Loh H.H. Dynorphin: a possible modulatory peptide on morphine or β-endorphin analgesia in mouse. Eur. J. Pharmacol. 69:1981;357-360.
52. Gustafsson H., Lucas G.A., Schött E., Stiller C.-O., Alster P., Wiesenfeld-Hallin Z., Brodin E. Peripheral axotomy influences the in vivo release of cholecystokinin in the spinal cord dorsal horn - possible involvement of cholecystokinin-B receptors. Brain Res. 790:1998;141-150.
53. Han J.S., Ding X.Z., Fan X.G. Cholecystokinin octapeptide (CCK-8): antagonism to electroacupuncture analgesia and a possible role in electroacupuncture tolerance. Pain. 27:1986;101-115.
54. Hill D.R., Hughes J., Pittaway K.M. Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: effects of naloxone and peptidase inhibitors. Neuropharmacol. 26:1987;289-300.
55. Hökfelt T., Zhang X., Wiesenfeld-Hallin Z. Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neurosci. 17:1994;22-30.
56. T. Hökfelt, X. Zhang, Z.-Q. Xu, J.-R. Rong, T. Shi, J. Corness, N. Kerekes, M. Landry, M. Rydh-Rinder, C. Broberger, Z. Wiesenfeld-Hallin, T. Bartfai, R. Elde, G. Ju, Cellular, synaptic mechanisms in transition of pain from acute to chronic, in: T.S. Jensen, J.A. Turner, Z. Wiesenfeld-Hallin (Eds.), Proceedings of the 8th World Congress on Pain, Progress in Pain Research and Management, vol. 8, IASP Press, Seattle, 1997, pp. 133-153.
57. Hu Z., Li Z.-V., Si J.-Q. Evidence for the existence of substance P autoreceptors in the membrane of rat dorsal root ganglion. Neuroscience. 77:1997;535-541.
58. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., Morris H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 258:1975;577-579.
59. Iadarola M.J., Brady L.S., Draisci G., Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioural parameters and opioid receptor binding. Pain. 35:1988;313-326.
60. Igwe O.J., Ning L. Regulation of the second-messenger systems in the rat spinal cord during prolonged peripheral inflammation. Pain. 58:1994;63-75.
61. Innis R.B., Snyder S.H. Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. U.S.A. 77:1980;6917-6921.
62. Itoh S., Katsuura G., Maeda Y. Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat. Eur. J. Pharmacol. 80:1982;421-425.
63. Jensen T.S., Yaksh T.L. Examination of spinal monoamine receptors through which braistem opiate-sensitive systems act in the rat. Brain Res. 363:1986;114-127.
64. Ji R.-R., Zhang Q., Law P.-Y., Low H.H., Elde R., Hökfelt T. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J. Neurosci. 15:1995;8156-8166.
65. Jin W., Lee N.M., Loh H.H., Thayer S.A. Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma X glioma hybrid NG 108-15 cells. Mol. Pharmacol. 42:1992;1083-1089.
66. Kastin A.J., Stephens E., Ehrensing R.H., Fischan A.J. Tyr-MIF-1 acts as an opiate antagonist in the tail-flick test. Pharmacol. Biochem. Behav. 21:1984;937-941.
67. Keith D.E., Anton B., Murray S.R., Zaki P.A., Chu P.C., Lissin D.V., Monteillet-Agius G., Stewart P.L., Evans C.J., von Zastrow M. Mu-Opioid receptor internalization: Opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol. Pharmacol. 53:1998;377-384.
68. Larssen L.J., Rehfeld J. Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Res. 165:1979;201-218.
69. Leah J., Menetrey D., de Pommery J. Neuropeptides in long ascending spinal tract cells in the rat: evidence for parallel processing of ascending information. Neuroscience. 24:1988;195-207.
70. Linderfors N., Linden A., Brene S., Sedvall G., Persson H. CCK peptides and mRNA in the human brain. Prog. Neurobiol. 40:1993;671-690.
71. Liu N.J., Xu T., Xu C., Li C.Q., Yu Y.X., Kang H.G., Han J.S. Cholecystokinin octapeptide reverses mu-opioid-receptor-mediated inhibition of calcium current in rat dorsal root ganglion neurons. J. Pharmacol. Exp. Therap. 275:1995;1293-1299.
72. Lombard M.C., Besse D., Chen Y.L., Besson J.M. Mu-opioid receptors in the superficial spinal dorsal horn in an experimental model of peripheral mononeuropathy in the rat. Eur. J. Pharmacol. 181:1990;2308-2318.
73. Lucas G.A., Alster P., Brodin E., Wiesenfeld-Hallin Z. Differential release of cholecystokinin by morphine in the rat spinal cord. Neurosci. Lett. 245:1998;13-16.
74. Lucas G.A., Xu X.-J., Wiesenfeld-Hallin Z. On the role of cholecystokinin in the mediation of spinal reflex excitability in intact and axotomized rats. Neuropeptides. 32:1998;73-78.
75. Maciewicz B., Phipps S., Grenier J., Poletti C.E. Edinger-Westphal nucleus: cholecystokinin immunocytochemistry and projections to spinal cord and trigeminal nucleus in the cat. Brain Res. 299:1984;139-145.
76. Mantyh P.W., Hunt S.P. Evidence for cholecystokinin-like immunoreactive neurons in rat medulla which project to the spinal cord. Brain Res. 291:1984;49-54.
77. Mao J., Price D.D., Mayer D.J., Hayes R.L. Pain-related increases in spinal cord membrane-bound protein kinase C following peripheral nerve injury. Brain Res. 588:1992;144-149.
78. Mao J., Mayer D.J., Hayes R.L., Price D.D. Spatial patterns of increased spinal cord membrane-bound protein kinase C and their relation to increases in 14C-2-deoxyglucose metabolic activity in rats with painful peripheral mononeuropathy. J. Neurophysiol. 70:1993;470-481.
79. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 383:1996;819-823.
80. L.M. Mendell, Physiological properties of unmyelinated fiber projection on the spinal cord, Exp. Neurol., (1966) 316-332.
81. Mercer L.D., Beart P.M. Histochemistry in rat and spinal cord with an antibody directed at the cholecystokinin (A) receptor. Neurosci. Lett. 4:1997;97-100.
82. Meyer D.K., Krauss J. Dopamine modulates cholecystokinin release in neostriatum. Nature. 301:1983;338-340.
83. Moran T.H., Schwartz G.J. Neurobiology of cholecystokinin. Crit. Rev. Neurobiol. 9:1994;1-28.
84. Mutt V., Jorpes J.E. Structure of porcine cholecystokinin-pancreozymin. Cleavage with trombin and with trypsin. Eur. J. Biochem. 6:1968;156-162.
85. Nielsch U., Keen U. Reciprocal regulation of tachykinin- and vasoactive intestinal peptide-gene expression in rat sensory neurons following cut and crush injury. Brain Res. 481:1989;25-30.
86. Noble F., Blommaert A., Fournie-Zaluski M.C., Roques B.P. A selective CCK-B receptor antagonist potentiates mu-, but not delta-opioid receptor-mediated antinociception in the formalin test. Eur. J. Pharmacol. 273:1995;145-151.
87. Noguchi K., Dubner R., Ruda M.A. Preproenkephalin mRNA in spinal dorsal horn neurons is induced by peripheral inflammation and is co-localized with Fos and Fos-related proteins. Neuroscience. 46:1992;561-570.
88. Noguchi K., Kowalski K., Traub R., Solodkin A., Iadarola M.J., Ruda M.A. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Mol. Brain Res. 10:1991;227-233.
89. North R.A., Willians J.T., Surprenant A., Christie M.J. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc. Nat. Acad. Sci. U.S.A. 84:1987;5487-5491.
90. 2+ system through cross-talk between opioid receptors and P2-purinergic or bradykinin receptors in NG 108-15 cells. Biochem. J. 290:1993;241-247.
91. Pan Z.Z., William J.T., Osborne P.B. Opioid actions on single nucleus raphe magnus neurons from rat and guinea-pig in vitro. J. Physiol. 427:1990;519-532.
92. Paudice P., Raiteri M. Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens. Br. J. Pharmacol. 103:1991;1790-1794.
93. Pinget M., Strauss E., Yalow R.S. Release of cholecystokinin peptides from synatosoma-enriched fraction of rat cerebral cortex. Life Sci. 25:1979;339-342.
94. Porreca F., Tang Q., Bian D., Riedl M., Elde R., Lai J. Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury. Brain Res. 795:1998;197-203.
95. Porzig H. Pharmacological modulation of voltage-dependent calcium channels in intact cells. Rev. Physiol. Biochem. Pharmacol. 114:1990;209-262.
96. Przewlocka B., Lason W., Przewlocki R. Time-dependent changes in the activity of opioid systems in the spinal cord of monoarthritic rats - a release and in situ hybridization study. Neuroscience. 46:1992;209-216.
97. Raffa R.B., Connelly C.D., Martinez R.P. Opioid efficacy is linked to LiCl-sensitive inositol-1,4,5-trisphosphate-restorable pathway. Eur. J. Pharmacol. 217:1992;221-223.
98. Raffa R.B., Martinez R.P. Morphine antinociception is mediated through a LiCl-sensitive, IP3-restorable pathway. Eur. J. Pharmacol. 215:1992;357-358.
99. Raiteri M., Paudice P., Vallebuona F. Release of cholecystokinin in the central nervous system. Neurochem. Int. 22:1993;519-527.
100. Ravovska N. Cholecystokinin-GABA interactions in rat striatum. Neuropeptides. 29:1995;257-262.
101. Reddy S.V., Maderdrut J.L., Yaksh T.L. Spinal cord pharmacology of adreneregic agonist-mediated antinociception. J. Pharmacol. Exp. Therap. 213:1980;525-533.
102. Rehfeld J.F. Immunochemical studies on cholecystokinin. I. Development of sequence-specific radioimmunoassays for porcine triacontatriapeptide cholecystokinin. J. Biol. Chem. 253:1978;4016-4021.
103. J.F. Rehfeld, H.F. Hansen, Cholecystokinin and gastrin peptides in the nervous system: post-translational processing of the precursos, in: J. De Belleroche, G.J. Dockray (Eds.), Cholecystokinin (CCK) in the nervous system, Ellis Horwood, Chichester, 1984, pp. 31-40.
104. Rodriguez R.E., Sacristan M.P. In vitro release of CCK-8 from the dorsal horn of the rat: inhibition by DAGO. FEBS Lett. 250:1989;215-217.
105. Rose C., Camus A., Schwartz J.C. Protection by serine peptidase inhibitors of endogenous cholecystokinin released from brain slices. Neuroscience. 29:1989;583-594.
106. Rose C., Vargas F., Facchinetti P., Bourgeat P., Bambal R.B., Bishop P.B., Chan S.M.T., Moore A.N.J., Ganellin C.R., Schwartz J.C. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature. 380:1996;403-409.
107. Ruda M.A., Iadarola M.J., Cohen L.V., Young W.S. In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal dynorphin biosynthesis in a rat model of peripheral inflammation and hyperalgesia. Proc. Nat. Acad. Sci. U.S.A. 8:1988;622-626.
108. Saito A.H., Sankaran H., Goldine I.D., Williams J.A. Cholecystokinin receptors in the brain: characterization and distribution. Science. 208:1980;1155-1156.
109. Schiffmann D., Vanderhaeghen J.J. Distribution of cells containing mRNA encoding cholecystokinin in the rat central nervous system. J. Comp. Neurol. 304:1991;219-233.
110. Segredo V., Burford N.T., Lameh J., Sadée W. A constitutively internalizing and recycling mutant of the mu-opioid receptor. J. Neurochem. 68:1997;2395-2404.
111. Shehab S.A.S., Atkinson M.E. Vasoactive intestinal polypeptide increases in areas of the dorsal horn of the spinal cord from which other neuropeptides are depleted following peripheral axotomy. Exp. Brain Res. 62:1986;422-430.
112. Skirboll L., Hökfelt T., Dockray G., Gehfeld J., Brownstein M., Cuello A.C. Evidence of periaqueductal cholecystokinin-substance P neurons projecting to the spinal cord. J. Neurosci. 3:1983;1151-1157.
113. Smart D., Smith G., Lambert D.G. Mu-opioid receptor stimulation of inositol (1,4,5)trisphosphate formation via a pertussis toxin-sensitive G protein. J. Neurochem. 62:1994;1009-1014.
114. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. U.S.A. 94:1997;1544-1549.
115. Stanfa L.C., Dickenson A.H. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenan inflammation. Br. J. Pharmacol. 108:1993;967-973.
116. Stanfa L., Dickenson A. Spinal opioid systems in inflammation. Inflamm. Res. 44:1995;231-241.
117. Stanfa L., Dickenson A., Xu X.-J., Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: Variations on a theme. Trends Pharmacol. Sci. 15:1994;65-66.
118. Stanfa L., Sullivan A.F., Dickenson A. Alterations in neuronal excitability and potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation. Pain. 50:1992;345-354.
119. Stein C., Millan M.J., Shippenberg T.S., Peter K., Herz A. Peripheral opioid receptors mediating antinociception in inflammation: evidence for involvement of mu, delta and kappa receptors. J. Pharmacol. Exp. Therap. 248:1992;1269-1275.
120. Stein C.S. Peripheral mechanism of opioid analgesia. Anesth. Analg. 76:1993;182-191.
121. Stevens C.W., Kajander K.C., Bennett G.J., Seybold V.S. Bilateral and differential changes in spinal mu, delta, and kappa opioid binding in rats with a painful, unilateral neuropathy. Pain. 46:1991;315-326.
122. Suberg S.N., Culhane E.S., Carstens E., Watkins L.R. The potentiation of morphine-induced inhibition of spinal transmission by proglumide, a putative cholecystokinin antagonist. Ann. N.Y. Acad. Sci. 448:1985;660-662.
123. Valverde O., Maldonado R., Fournie-Zaluski M.C., Roques B.P. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmacol. Exp. Therap. 270:1994;77-88.
124. 5(enkephalin antiserum-sensitive enhancement of morphine antinociception. NeuroReport. 5:1994;1-5.
125. Vanderhaeghen J.J., Deschepper C., Lotstra F., Vierendeels G., Schoenen J. Immunohistochemical evidence for cholecystokinin-like peptides in neuronal cell bodies of the rat spinal cord. Cell Tissue Res. 223:1982;463-467.
126. Vanderhaegen J.J., Signeau J.C., Gepts W. A new peptide in the vertebrate CNS reacting with antigastrin antibodies. Nature. 257:1975;604-605.
127. Vaught J.L., Takemori A.E. A further characterizatoin of the differential effects of leucine enkephalin, methionine enkephalin and their analogs on morphine-induced analgesia. J. Pharmacol. Exp. Therap. 211:1979;280-283.
128. Verge V.M.K., Wiesenfeld-Hallin Z., Hökfelt T. Cholecystokinin in mammalian primary sensory neurons and spinal cord: in situ hybridization studies on rat and monkey spinal ganglia. Eur. J. Neurosci. 5:1992;240-250.
129. Verhage M., Ghijsen W.E.J.M., Nicholls D.G., Wiegant V.M. Characterization of the release of cholecystokinin-8 from isolated nerve terminals and comparison with exocytosis of classical transmitters. J. Neurochem. 56:1991;1394-1400.
130. Vizi E.S., Harsing L.G., Knoll J. Inhibitory effect of dopamine on acetylcholine release from caudate nucleus. Pol. J. Pharmacol. Pharm. 29:1977;201-211.
131. Wall P.D., Woolf C.J. Muscle but not cutaneous C-afferent input produces prolonged increases in the excitability of the flexion reflex in the rat. J. Physiol. 356:1984;443-458.
132. Wang J.F., Ren M.F., Han J.S. Mobilization of calcium from intracellular stores is one of the mechanisms underlying the anti-opioid effect of cholecystokinin octapeptide. Peptides. 13:1992;947-951.
133. Wang X.J., Fan S.G., Ren M.F., Han J.S. Cholecystokinin-8 suppressed 3H-etorphine binding to rat brain opiate receptors. Life Sci. 45:1989;117-123.
134. Wang X.J., Han J.S. Modification by cholecystokinin octapeptide of the binding of mu-, delta-, and kappa-opioid receptors. J. Neurochem. 55:1990;1379-1382.
135. Wang X.J., Wang X.H., Han J.S. Cholecystokinin octapeptide antagonized opioid analgesia mediated by mu and kappa- but not delta-receptor in rat spinal cord. Brain Res. 523:1990;5-10.
136. Wank S.A. Cholecystokinin receptors. Am. J. Physiol. 269:1995;G628-646.
137. Watkins L.R., Kinscheck I.B., Mayer D.J. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science. 224:1984;395-396.
138. Watkins L.R., Kinscheck I.B., Kaufman E.F., Miller J., Frenk H., Mayer D.J. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res. 327:1985;181-190.
139. Wiesenfeld-Hallin Z., Xu X.-J. The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance. Reg. Peptides. 65:1996;23-28.
140. Wiesenfeld-Hallin Z., Xu X.-J., Håkanson R., Feng D.-M., Folkers K. Plasticity of the peptidergic mediation of spinal reflex facilitation after peripheral nerve section in the rat. Neurosci. Lett. 116:1990;293-298.
141. Wiesenfeld-Hallin Z., Xu X.-J., Hughes J., Horwell D.C., Hökfelt T. PD134308, a selective antagonist of cholecystokinin type-B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Natl. Acad. Sci. U.S.A. 87:1990;7105-7109.
142. Wiesenfeld-Hallin Z., Xu X.-J., Villar M.J., Hökfelt T. Intrathecal galanin potentiates the spinal analgesic effect of morphine: electrophysiological and behavioural studies. Neurosci. Lett. 109:1990;217-221.
143. J. Willets, K. Urban, K. Murase, M. Randic, Actions of cholecystokinin octapeptide on rat spinal dorsal horn neurons, in: J.J. Vanderhaeghen, J.C., Crawley (Eds.), Neuronal Cholecystokinin, Ann. N.Y. Acad. Sci. 448 (1985) 385-401.
144. Woodruff G.N., Hill D.R., Boden P., Pinnock R., Singh L., Hughes J. Functional role of brain CCK receptors. Neuropeptides. 19:1991;45-56.
145. C.J. Woolf, Excitability changes in central neurons following peripheral damage, in: W.D. Willis (Ed.), Hyperalgesia and Allodynia, Raven Press, New York, 1992, pp. 221-243.
146. Woolf C.J., Thompson S.W.N. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity state. Pain. 44:1991;293-299.
147. Woolf C.J., Wiesenfeld-Hallin Z. Substance P and calcitonin gene-related peptide synergistically modulate the gain of the nociceptive flexor withdrawal reflex in the rat. Neurosci. Lett. 66:1986;319-323.
148. Xu T., Liu N.J., Li C.Q., Shangguan Y., Yu Y.X., Kang H.G., Han J.S. Cholecystokinin octapeptide reverses the kappa-opioid-receptor-mediated depression of calcium current in rat dorsal root ganglion neurons. Brain Res. 730:1996;207-211.
149. Xu X.-J., Maggi C.A., Wiesenfeld-Hallin Z. On the role of NK-2 tachykinin receptors in the mediation of spinal reflex excitability inthe rat. Neuroscience. 44:1991;483-490.
150. Xu X.-J., Puke M.J.C., Verge V.M.K., Wiesenfeld-Hallin Z., Hughes J., Hökfelt T. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci. Lett. 152:1993;129-132.
151. Yaksh T.L. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesth. Scand. 41:1997;94-111.
152. Yaksh T.L., Abay E.O., Go V.L.W. Studies on the location and release of cholecystokinin and vasoactive intestinal peptide in rat and cat spinal cord. Brain Res. 242:1982;279-290.
153. Yaksh T.L., Furui T., Kanawati I.S., Go V.L.W. Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems. Brain Res. 406:1987;207-214.
154. Yaksh T.L., Rudy T.A. Studies on the direct spinal action of narcotics in the production of analgesia in the rat. J. Pharmacol. Exp. Therap. 202:1977;411-428.
155. Yaksh T.L., Rudy T.A. Analgesia mediated by a direct spinal action of narcotics. Science. 192:1977;1357-1358.
156. Yamamoto T., Nozakitaguchi N. Role of cholecystokinin-B receptor in the maintenance of thermal hyperalgesia induced by unilateral constriction injury to the sciatic nerve in the rat. Neurosci. Lett. 202:1995;89-92.
157. Yang H.Y.T., Fratta W., Majane E.A., Costa E. Isolation, sequencing, synthesis and pharmacological characterization of two brain neuropeptides that modulate the actions of morphine. Proc. Natl. Acad. Sci. U.S.A. 82:1985;7757-7761.
158. Yang J.T., Thomas N.D., Helke C.J. Characterization of substance P release from intermediate area of rat thoracic spinal cord. Synapse. 23:1996;265-273.
159. Zadina J.E., Hackler L., Ge L.J., Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature. 386:1997;499-502.
160. Zhang X., Bao L., Shi T.-J., Ju G., Elde R., Hökfelt T. Downregulation of μ-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy. Neuroscience. 82:1998;223-240.
161. Zhang X., Dagerlind Å., Elde R., Castel M.-N., Broberger C., Wiesenfeld-Hallin Z., Hökfelt T. Marked increase in cholecystokinin B receptor messenger RNA levels in rat dorsal root ganglia after peripheral axotomy. Neuroscience. 57:1993;233-337.
162. Zhou Y., Sun Y.H., Zhang Z.W., Han J.S. Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine. NeuroReport. 3:1992;1121-1123.
163. Zhou Y., Sun Y.H., Zhang Z.W., Han J.S. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCKB receptor antagonist L365,260 in rat spinal cord. Eur. J. Pharmacol. 234:1993;147-154.
164. Zieglgänsberger W., French E.D., Siggins G.R., Bloom F.E. Opioid peptides may excite hippocampal pyramidal neurons by inhibiting adjacent inhibitory interneurons. Science. 205:1979;415-417.
165. Zieglgänsberger W., Tölle T.R. The pharmacology of pain signalling. Curr. Op. Neurobiol. 3:1993;611-618.